Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

Chronic Telogen Effluvium can be managed by avoiding inflammatory foods, exercising, staying hydrated, and using supplements like krill oil, saw palmetto, or licorice root. Minoxidil is discouraged due to its cost and potential for worsening hair loss, while castor oil is recommended to strengthen hair roots and reduce shedding.

Hair loss is primarily genetic, and nutrient deficiencies are unlikely to be the cause. DHT inhibitors can slow hair loss, but concerns about side effects are common.

Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.

Finasteride and minoxidil are recommended for hair loss, with skepticism about additional treatments like electro stimulation and oxygen infusion, which are seen as ineffective and costly. Pulsed ultrasound may enhance drug delivery, but most other treatments are considered ineffective.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

User discusses tight scalp causing hair loss and suggests treatments like scalp massages, PRP, saw palmetto, and eucapil. They share their experience with saw palmetto and eucapil and consider adding PRP and scalp massages for better results.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

The conversation is about hair loss treatments, including minoxidil, finasteride, dutasteride, tretinoin, stemoxydine, adenosine, castor oil, baicalin, and bimatoprost. The user shares their nightly and morning routines and discusses the role of DHT in hair loss.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

Treating hair loss with various remedies, such as Cetirizine and the Big3 complex (minoxidil, finasteride, and RU58841), which have properties like adipogenic, anti-fibrotic and anti-inflammatory. References to research studies are also included.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

Quercetin and houttuynia cordata extract may stimulate hair growth by enhancing cellular energy metabolism and increasing growth factor secretion. Quercetin has low oral bioavailability, and its natural tint might stain the scalp if used topically.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

After two years of no regrowth with oral finasteride and topical minoxidil, adding topical finasteride and dermastamping led to noticeable hair regrowth in one month. The combination of treatments, particularly the addition of topical finasteride and dermastamping, is believed to have improved absorption and effectiveness.

Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.

Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Treatments for hair loss, such as using AR receptor blockers and degraders, to see if follicles can regenerate in the long term. The conversation also discusses how hair transplants could be a potential solution.

Factors that can cause hair loss other than DHT, such as inflammation and diet, and potential treatments like scalp massages, minoxidil, citrulline, stretches, meditation, iron sulfate/Vitamin C, Vitamin D, protein and Dutasteride.

KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.

A user is considering an extensive hair loss treatment regimen including oral dutasteride, oral minoxidil, topical finasteride, tretinoin, microneedling, keto shampoo, laser comb, and PRP injections. Suggestions include simplifying the routine, possibly increasing minoxidil dosage, and considering alternatives like RU58841, while cautioning against using estrogen due to potential side effects.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The user has been using liposomal topical finasteride since late 2022, progressively increasing the dose, but DHT serum levels remain largely unchanged. Despite using finasteride, minoxidil, microneedling, and ketoconazole, hair condition has neither improved nor worsened.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.